Product Information
ERYTHROMYCIN 400 MG/5 ML SUSP is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $1.7436 per ML under NDC 62559063101. Its NADAC has been published 237 times since Mar 23, 2022.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/5mL
Manufacturer
ANI Pharmaceuticals, Inc.NDC
62559063101
Classification
Generic
Dosage Form
GRANULE, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ERYTHROMYCIN ETHYLSUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA062055FDA Approved
Before 1982
TE Code
AB
On Market Since
3/25/2019
Pharmacological Classes
Price Statistics
The NADAC for ERYTHROMYCIN 400 MG/5 ML SUSP has been published 237 times since Mar 23, 2022, and over the history we have for it it has declined 43.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.7436 per ML |
|---|---|
| All-time high | $3.0813 (Aug 10, 2022) |
| All-time low | $1.7254 (Aug 19, 2026) |
| 52-week high | $2.2830 |
| 52-week low | $1.7254 |
| Median price | $2.2149 |
| Average price | $2.3076 |
| Largest weekly change | -20.3% (Apr 17, 2024) |
| Weeks tracked | 237 |
| Tracking since | Mar 23, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Erythromycin Ethylsuccinate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Erythromycin Ethylsuccinate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERYTHROMYCIN 400 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for ERYTHROMYCIN 400 MG/5 ML SUSP, manufactured by ANI Pharmaceuticals, Inc., is $1.7436 per ML (NDC 62559063101), effective Sep 30, 2026.
How has the price of ERYTHROMYCIN 400 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for ERYTHROMYCIN 400 MG/5 ML SUSP has declined 43.4%. It has been tracked across 237 weekly CMS publications since Mar 23, 2022.
What are the highest and lowest recorded NADAC prices for ERYTHROMYCIN 400 MG/5 ML SUSP?
Since Mar 23, 2022, the NADAC for ERYTHROMYCIN 400 MG/5 ML SUSP has ranged from a low of $1.7254 (Aug 19, 2026) to a high of $3.0813 (Aug 10, 2022), with a median of $2.2149 per ML.
Are there cheaper alternatives to ERYTHROMYCIN 400 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of ERYTHROMYCIN 400 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ERYTHROMYCIN 400 MG/5 ML SUSP?
ERYTHROMYCIN 400 MG/5 ML SUSP (NDC 62559063101) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.